Results 241 to 250 of about 985,459 (298)

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies. [PDF]

Blood Lymphat Cancer
Reynolds SB, Komrokji R, Kuykendall AT.
europepmc   +1 more source

JAK Inhibitor Therapy

Oncology Times, 2019
openaire   +2 more sources

Novel <i>USP18</i> mutations lead to severe interferonopathy responsive to JAK inhibitor. [PDF]

Front Immunol
Sun X, Li M, Dou Y, Wang Q, Lai J, Zhu J, Zhou Q, Yu X.   +7 more
europepmc   +1 more source

Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive. [PDF]

Allergy
Deng Y, Leib N, Schnautz S, Benfadal S, Oldenburg J, Bieber T, Herrmann N.   +6 more
europepmc   +1 more source

Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry. [PDF]

ACR Open Rheumatol
Baker JF, Mizelle KV, Saikali W, Moore PC, Kang HJ, Gruben D, Shelbaya A, Stockert L, O'Brien J.   +8 more
europepmc   +1 more source

Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use. [PDF]

J Vitreoretin Dis
Apel W, Li Y.
europepmc   +1 more source

Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors.

JAMA Dermatol
Kalil L, Craiglow BG, King B.
europepmc   +1 more source

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the less frequent intestinal and ocular manifestations with ...
Luisa Costa, Sara Cacciapuoti, Angelo Ruggiero   +2 more
exaly   +7 more sources